ANI Pharmaceuticals Proposes $560 Million Acquisition of Egetis Therapeutics

ANI Pharmaceuticals has made a public offer to acquire Egetis Therapeutics AB for approximately $560 million, or SEK 5.6 billion. The deal, which has the unanimous recommendation of Egetis's Board and support from major shareholders, aims to expand ANI's rare disease business, enhance clinical development, and diversify revenue. This strategic move leverages ANI's existing infrastructure in the rare disease sector.